Ulinastatin in the treatment of severe acute pancreatitis: A singlecenter randomized controlled trial

BACKGROUND Severe acute pancreatitis(AP) is one of the most common diseases of the gastrointestinal tract and carries a significant financial burden with high disability and mortality. There are no effective drugs in the clinical management of severe AP, and there is an absence of evidence-based medicine concerning the treatment of severe AP.AIM To explore whether ulinastatin(UTI) can improve the outcome of severe AP.METHODS The present research included patients who were hospitalized in intensive critical care units(ICUs) after being diagnosed with severe AP. Patients received UTI(400000 IU) or placebos utilizing computer-based random sequencing(in a 1:1 ratio). The primary outcome measures were 7-d mortality, clinical efficacy, inflammatory response, coagulation function, infection, liver function, renal function, and drug-related adverse effects were evaluated.RESULTS A total of 181 individuals were classified into two groups, namely, the placebo group(n = 90) and the UTI group(n = 91). There were no statistically significant differences in baseline clinical data between the two groups. The 7-d mortality and clinical efficacy in the UTI group were remarkably improved compared with those in the placebo group. UTI can protect against hyperinflammation and improve coagulation dysfunction, infection, liver function, and renal function. UTI patients had markedly decreased hospital stays and hospitalization expenditures compared with the placebo group.CONCLUSION The findings from the present research indicated that UTI can improve the clinical outcomes of patients with severe AP and has fewer adverse reactions.